Ketamine/propofol admixture vs etomidate for intubation in the critically ill: KEEP PACE Randomized clinical trial

• Published in: The journal of trauma and acute care surgery Vol. 87; no. 4; pp. 883 - 891
• Main Authors: Smischney, Nathan Jerome, Nicholson, Wayne T, Brown, Daniel R, Gallo De Moraes, Alice, Hoskote, Sumedh S, Pickering, Brian, Oeckler, Richard A, Iyer, Vivek N, Gajic, Ognjen, Schroeder, Darrell R, Bauer, Philippe R
• Format: Journal Article
• Language: English
• Published: United States 01-10-2019
• Subjects: Adult; Anesthetics, Intravenous; Critical Illness - therapy; Dose-Response Relationship, Drug; Drug Monitoring - methods; Drug Therapy, Combination - methods; Emergency Medical Services - methods; Etomidate - administration & dosage; Etomidate - adverse effects; Female; Hemodynamics - drug effects; Humans; Hypnotics and Sedatives - administration & dosage; Hypnotics and Sedatives - adverse effects; Hypotension - diagnosis; Hypotension - drug therapy; Hypotension - etiology; Intubation, Intratracheal - adverse effects; Intubation, Intratracheal - methods; Ketamine - administration & dosage; Ketamine - adverse effects; Male; Middle Aged; Propofol - administration & dosage; Propofol - adverse effects; Treatment Outcome
• ISSN: 2163-0755; 2163-0763
• DOI: 10.1097/TA.0000000000002448

Periintubation hypotension is associated with poor outcomes in the critically ill. We aimed to determine if an admixture of ketamine and propofol for emergent endotracheal intubation in critically ill patients was superior to etomidate. Primary endpoint was the change in mean arterial pressure from baseline to 5 minutes postdrug administration.
Emergent-use, stratified (shock status and unit type), multiunit, randomized, parallel-group superiority clinical trial was conducted at a tertiary academic medical center. Adult medical/surgical and transplant/oncologic intensive care unit patients undergoing emergent intubation were assigned randomly to receive either ketamine/propofol admixture (0.5 mg/kg of ketamine and propofol each) or reduced dose etomidate (0.15 mg/kg) for emergent intubation.
One hundred sixty participants were randomized, and 152 (79 ketamine/propofol admixture, 73 etomidate) were included in the intention-to-treat analysis. There was no statistically significant difference in mean arterial pressure change from baseline to 5 minutes postdrug administration (treatment difference [ketamine/propofol admixture-etomidate]: -2.1 mm Hg; 95% confidence interval, -6.9 mm Hg to +2.7 mm Hg; p = 0.385). In addition, no statistically significant difference was demonstrated in the change of mean arterial pressure from baseline at 10 minutes and 15 minutes postdrug administration, no statistical difference in the use of new-onset vasoactive agents or difficulty of intubation between groups. More patients in the etomidate group required non-red blood cell transfusions (16 [22%] vs. 8 [10%], p = 0.046). For patients who had adrenal testing performed, more patients in the etomidate group developed immediate adrenal insufficiency (13 [81%] of 16 vs. 5 [38%] of 13, p = 0.027). Serious adverse events were rare, 2 (3%) (cardiac arrest, hypotension) in ketamine/propofol admixture and 4 (5%) (hypertension, hypotension) in etomidate (p = 0.430).
In a heterogeneous critically ill population, ketamine/propofol admixture was not superior to a reduced dose of etomidate at preserving per-intubation hemodynamics and appears to be a safe alternative induction agent in the critically ill.
Therapeutic/Care Management, level II.
ClinicalTrials.gov, NCT02105415, Ketamine/Propofol Admixture "Ketofol" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial, IRB 13-000506, Trial Registration: March 31, 2014.